title: Liver transplantation in human immunodeficiency virus-positive patients.
abstract: With the successful introduction of combined antiretroviral therapy (cART), human immunodeficiency virus (HIV) is now regarded as a chronic illness with excellent long-term outcomes. However, chronic exposure to viral etiologies (ie, chronic hepatitis B and hepatitis C) and drug-induced toxicity secondary to cART have resulted in increasing rates of mortality and morbidity due to end-stage liver disease. HIV disease is no longer considered an absolute contraindication to liver transplantation (LT) by most transplant centers worldwide. Because the burden of liver disease in this cohort is likely to increase, this review addresses the key etiologies and the management strategies available for HIV-positive patients undergoing LT.
authors.affiliation: Institute of Liver Studies, King's College Hospital, Denmark Hill, London, SE5 9RS, UK.
authors.forename: Deepak
authors.initials: D
authors.lastname: Joshi
authors.forename: John
authors.initials: J
authors.lastname: O'Grady
authors.forename: Chris
authors.initials: C
authors.lastname: Taylor
authors.forename: Nigel
authors.initials: N
authors.lastname: Heaton
authors.forename: Kosh
authors.initials: K
authors.lastname: Agarwal
mesh_terms: D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D005060:Europe; D015658:HIV Infections / Q000150:complications*; D006679:HIV Seropositivity / Q000150:complications*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D017093:Liver Failure / Q000601:surgery / Q000628:therapy*; D016031:Liver Transplantation / Q000379:methods*; D015995:Prevalence; D016896:Treatment Outcome; D014481:United States
chemical_list: D044966:Anti-Retroviral Agents